Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction

12 novembre 2026 mis à jour par: South Rampart Pharma, Inc.

A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction

This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.

Aperçu de l'étude

Description détaillée

This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).

Type d'étude

Interventionnel

Inscription (Estimé)

130

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: CenExel JBR Recruiting

Lieux d'étude

    • Utah
      • Salt Lake City, Utah, États-Unis, 84107
        • CenExel JBR Clinical Research
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 50 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Is male or female ≥ 18 and ≤ 50 years of age.
  • Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
  • Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
  • Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
  • Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
  • Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
  • Able to provide written informed consent.
  • Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)

Exclusion Criteria:

  • Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
  • History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
  • Complications from tooth extraction resulting in a "severe" surgical trauma rating.
  • Dental surgery within 60 days prior to Day 1.
  • Positive urine drug screen or alcohol breathalyzer test.
  • Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
  • Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
  • Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ‭≥ 4 weeks prior to Screening.‬‬‬‬‬‬‬‬‬‬‬
  • History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
  • Difficulty swallowing oral medication.
  • Investigational drug exposure within 30 days or 5 half-lives.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: SRP-001

SRP-001 Single Oral Suspension dose of 2,000 mg

SRP-001 Oral Suspension

Comparateur placebo: Matching Placebo for SRP-001

Matching Placebo for SRP-001 Oral Suspension

Matching Placebo for SRP-001 Oral Suspension

Autres noms:
  • Contrôler

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Délai: 0 to 6 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo.

0 to 6 hours post-dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Délai: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse)

0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
Sum of pain relief (TOTPAR)
Délai: O to 2, 0 to 4, 0 to 6 and 0-8 hours.

Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose.

O to 2, 0 to 4, 0 to 6 and 0-8 hours.
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Délai: 0 to 8 hours post-dose

Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Délai: 0 to 8 hours post-dose

Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to first use of rescue medication
Délai: 0 - 6, 0-8, 0-24 hours post dose.

Rescue medication time for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Total rescue medication consumption
Délai: 0 - 6, 0-8, 0-24 hours post dose.

Total rescue medication consumption for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Day 1 through Follow-up Visit (Day 8 ± 2 days)

Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication

Day 1 through Follow-up Visit (Day 8 ± 2 days)
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Délai: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose

Pain intensity difference (PID) Scale is -10 to 10 (higher is better)

0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
Patient's global evaluation of study drug using a 5 point categorical scale
Délai: Up to 6 hours post dose

Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent

Up to 6 hours post dose
Number of participants with clinically significant abnormalities in laboratory abnormalities
Délai: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2

Number of participants with laboratory values judged clinically significant by the investigator in the following panels:

Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential)

Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
Maximum Observed Plasma Concentration (CMax) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Time to maximum observed plasma concentration (Tmax) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Délai: Pre-dose through 12 hours post-dose

AUC0-12 of SRP-001 following a single 2,000mg oral dose.

Pre-dose through 12 hours post-dose
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-t of SRP001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-inf of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Terminal elimination half life (t 1/2) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

t 1/2 of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent oral clearance (CL/F) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CL/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Vz/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Pain relief difference (PR)

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Time to first perceptible relief and time to confirmed perceptible pain relief
Délai: 0-4.5 hours post dose

TPPR and TCPR via stopwatch 1

0-4.5 hours post dose
Time to meaningful relief
Délai: 0-4.5 hours post dose

TMPR via Stopwatch 2

0-4.5 hours post dose
Time to complete pain relief
Délai: 0 to 8 hours post-dose

TCOMPR, NPRS = 0

0 to 8 hours post-dose

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Todd M Bertoch, MD, CenExel JBR Clinical Research

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 novembre 2026

Achèvement primaire (Estimé)

28 février 2027

Achèvement de l'étude (Estimé)

28 février 2027

Dates d'inscription aux études

Première soumission

4 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner